#ASH20: David Altshuler and the Vertex/CRISPR team hit a historic milestone in the hunt for a curative gene editing approach to sickle cell disease, beta thalassemia

John Carroll

Editor & Founder

Back in the mid-80s, David Altshuler worked in Richard Mulligan’s famous Harvard lab, focused on hemoglobinopathies and the glimmering promise of a gene therapy for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASH20: David Altshuler and the Vertex/CRISPR team hit a historic milestone in the hunt for a curative gene editing approach to sickle cell disease, beta thalassemia

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Roivant brings rare disease program closer as Immunovant CEO retires

China startup injects CRISPR therapy into the brain for the first time

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

#ASH20: David Alt­shuler and the Ver­tex/CRISPR team hit a his­toric mile­stone in the hunt for a cu­ra­tive gene edit­ing ap­proach to sick­le cell dis­ease, be­ta tha­lassemia

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

#ASH20: David Altshuler and the Vertex/CRISPR team hit a historic milestone in the hunt for a curative gene editing approach to sickle cell disease, beta thalassemia